UPDATE 1-Bayer sues Johnson & Johnson over marketing of prostate cancer drug

Johnson & Johnson +0.90% Post

Johnson & Johnson

JNJ

240.10

240.25

+0.90%

+0.06% Post

Recasts; adds accusations in complaint, changes dateline to NEW YORK

NEW YORK, Feb 23 (Reuters) - Bayer BAYGn.DE sued Johnson & Johnson JNJ.N on Monday, accusing the rival drugmaker of falsely advertising a drug intended to treat prostate cancer.

According to a complaint filed in Manhattan federal court, Johnson & Johnson launched a false advertising campaign against Bayer's Nubeqa drug, in order to promote and demonstrate the alleged superiority of its own drug, Erleada.

Bayer is seeking triple damages, the recoupment of alleged ill-gotten profits, and an injunction to stop Johnson & Johnson's alleged false advertising.

Johnson & Johnson did not immediately respond to a request for comment.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.